Abstract:
PURPOSE: An oxide thin film transistor biosensor is provided to show reliability and reproducibility, superior resistance to environmental stress and heat, and superior electrical characteristics. CONSTITUTION: A field effect transistor comprises: a substrate (200); a gate electrode (210) which is formed on the substrate; a gate insulation film (220) which is formed on the gate electrode; an oxide semiconductor layer (230) which is formed on the gate insulation film; and a source (240) and a drain electrode (250) which are formed on the oxide semiconductor layer to expose the oxide semiconductor layer. A field effect transistor biosensor detects components of a biomaterial (260) through current-voltage characteristics by bonding the biomaterial to a part of the oxide semiconductor layer which is exposed between the source and the drain electrode.
Abstract:
PURPOSE: The pharmaceutical composition for prevention or treatment of lupus nephritis including SRAGE as active ingredient is provided to show excellent effects of medical treatment in lupus nephritis by effectively reducing amount of proteinuria inside the textus renalis in immunocomplex deposition, and inside the concentrated blood serum claim -dsDNA antibody. CONSTITUTION: The pharmaceutical composition for prevention or treatment of lupus nephritis comprises the first sequence which unites ligand of receptor for advanced glycation end products: RAGE and soluble RAGE (sRAGE) as an active ingredient. The sRAGE of sequence listing first sequence obstructs bond between ligand of RAGE and RAGE. The sRAGE is combined with heavy chain of 7S antibody and Fc site of antibody The Fc site of antibody is Fc site of human immune globulin G1.
Abstract:
PURPOSE: A pharmaceutical composition for preventing or treating myocarditis is provided to effectively reduce inflammation and to treat myocarditis. CONSTITUTION: A pharmaceutical composition for preventing or treating myocarditis contains soluble receptor for advanced glycation end products (sRAGE) as an active ingredient, with an amino acid sequence of sequence number 1 which binds to a ligand of RAGE. The sRAGE interrupts a bond between RAGE and the ligand of RAGE. The sRAGE is conjugated with a heavy chain of immunoglobulin G and an Fc region of an antibody.
Abstract:
본 발명은 sRAGE를 유효성분으로 포함하는 심근염(Myocarditis)의 예방 또는 치료용 약제학적 조성물을 제공한다. 본 발명의 sRAGE는 면역글로블린 G의 중쇄(Heavy chain) 및 항체의 Fc 부위와 결합되어 있는 융합단백질로 제공되며, RAGE의 리간드와 RAGE 사이의 결합을 방해한다. 본 발명의 조성물은 심근의 염증반응을 억제시킴으로써 심근염에서 우수한 치료효과를 나타낸다.